U.S. patent application number 15/115606 was filed with the patent office on 2017-03-09 for anticancer agent composition.
The applicant listed for this patent is CARNA BIOSCIENCES, INC.. Invention is credited to Tokiko ASAMI, Yoko FUNAKOSHI, Masaaki SAWA, Chika TANAKA.
Application Number | 20170065609 15/115606 |
Document ID | / |
Family ID | 53756929 |
Filed Date | 2017-03-09 |
United States Patent
Application |
20170065609 |
Kind Code |
A1 |
FUNAKOSHI; Yoko ; et
al. |
March 9, 2017 |
ANTICANCER AGENT COMPOSITION
Abstract
Provided is a pharmaceutical composition comprising a Cdc7
inhibitor and an M phase promoter. In particular, the Cdc7
inhibitor contained in the pharmaceutical composition is a furanone
derivative represented by formula (I), or a pharmaceutically
acceptable salt thereof. (In the formula, A is --COOR1 or a
hydrogen atom; R1 is a hydrogen atom, an optionally substituted
hydrocarbon group, or an optionally substituted heterocycle; R2 and
R3 are the same or different and are each a hydrogen atom, an
optionally substituted hydrocarbon group, an optionally substituted
phenyl group, an optionally substituted heterocycle, an optionally
substituted heterocyclic condensed ring, or an optionally
substituted amino group. Alternatively, R2 and R3 may, together
with the nitrogen atoms bonding the same, form an optionally
substituted heterocycle or optionally substituted heterocyclic
condensed ring. R4 is a hydrogen atom or halogen atom. However, if
A is --COOR1, R2 and R3 are not both simultaneously optionally
substituted amino groups. When A is a hydrogen atom, R3 is a
hydrogen atom.)
Inventors: |
FUNAKOSHI; Yoko; (Hyogo,
JP) ; TANAKA; Chika; (Hyogo, JP) ; ASAMI;
Tokiko; (Hyogo, JP) ; SAWA; Masaaki; (Hyogo,
JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CARNA BIOSCIENCES, INC. |
|
|
|
|
|
Family ID: |
53756929 |
Appl. No.: |
15/115606 |
Filed: |
January 26, 2015 |
PCT Filed: |
January 26, 2015 |
PCT NO: |
PCT/JP2015/051987 |
371 Date: |
July 29, 2016 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
A61K 31/496 20130101; A61P 43/00 20180101; A61K 31/519 20130101;
A61K 31/4725 20130101; A61K 31/506 20130101; A61K 31/553 20130101;
A61K 31/395 20130101; A61K 31/5377 20130101; A61K 45/06 20130101;
A61K 31/444 20130101; A61P 35/02 20180101; A61K 31/437 20130101;
A61K 31/5377 20130101; A61K 2300/00 20130101; A61K 31/4725
20130101; A61K 2300/00 20130101; A61K 31/496 20130101; A61K 2300/00
20130101; A61K 31/506 20130101; A61K 2300/00 20130101; A61K 31/519
20130101; A61K 2300/00 20130101; A61K 31/444 20130101; A61K 2300/00
20130101 |
International
Class: |
A61K 31/553 20060101
A61K031/553; A61K 31/519 20060101 A61K031/519; A61K 31/395 20060101
A61K031/395; A61K 31/4725 20060101 A61K031/4725; A61K 31/444
20060101 A61K031/444; A61K 31/506 20060101 A61K031/506; A61K 31/496
20060101 A61K031/496; A61K 31/5377 20060101 A61K031/5377 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 31, 2014 |
JP |
2014-018075 |
Claims
1. A pharmaceutical composition comprising a Cdc7 inhibitor and an
M-phase promoter.
2. The pharmaceutical composition according to claim 1, wherein the
Cdc7 inhibitor is a furanone derivative represented by the
following formula (I): ##STR00020## wherein A represents --COOR1 or
a hydrogen atom; R1 represents a hydrogen atom, a hydrocarbon group
optionally having a substituent, or a heterocyclic ring optionally
having a substituent; R2 and R3 are the same or different and each
represent a hydrogen atom, a hydrocarbon group optionally having a
substituent, a phenyl group optionally having a substituent, a
heterocyclic ring optionally having a substituent, a heterocyclic
fused ring optionally having a substituent, or an amino group
optionally having a substituent, or R2 and R3 optionally form a
heterocyclic ring optionally having a substituent or a heterocyclic
fused ring optionally having a substituent, together with the
nitrogen atom bonded thereto; and R4 represents a hydrogen atom or
a halogen atom, provided that when A represents --COOR1, R2 and R3
do not represent the amino group optionally having a substituent at
the same time, and when A represents a hydrogen atom, R3 represents
a hydrogen atom, or a pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition according to claim 2, wherein the
A is --COOR1.
4. The pharmaceutical composition according to claim 2, wherein the
A is a hydrogen atom.
5. The pharmaceutical composition according to claim 3, wherein the
furanone derivative has the structure of the following compound
(I-A), compound (I-B), compound (I-C), compound (I-D), or compound
(I-E): formula (I-A): isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,-
5-dihydrofuran-3-carboxylate ##STR00021## formula (I-B): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(7-methoxy-3,4-dihydroisoq-
uinolin-2(1H)-yl)-4-oxo-4,5-dihydrofuran-3-carboxylate ##STR00022##
formula (I-C): isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
##STR00023## formula (I-D): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
##STR00024## and formula (I-E): cyclopropylmethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,
5-dihydrofuran-3-carboxylate ##STR00025##
6. The pharmaceutical composition according to claim 1, wherein the
Cdc7 inhibitor is any of the following compounds: formula (I-F):
2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone
##STR00026## and formula (I-G):
5-(2-amino-pyrimidin-4-yl)-2-(2,4-dichloro-phenyl)-1H-pyrrole-3-carboxyli-
c acid amide ##STR00027##
7. The pharmaceutical composition according to any one of claims 1
to 6, wherein the M-phase promoter is a Wee1 inhibitor.
8. The pharmaceutical composition according to claim 7, wherein the
Wee1 inhibitor is MK-1775 ##STR00028## miR-424, miR-381,
6-butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-d-
ione,
9-methoxy-4-(2-methoxy-5-nitrophenyl)-4,5,6,10c-tetrahydropyrrolo[3,-
4-c]carbazole-1,3(2H,3aH)-dione,
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]benzenesulfonamide,
4-(2,6-dichlorophenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]carbazo-
le-1,3(2H,6H)-dione,
4-(2,6-dichlorophenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-(1H)-yl)-N-(1 H-tetrazol-5-yl)propanamide,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfinyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
6-(3-bromopropyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoic acid,
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]-2-(dimethylamino)ethanesulfonamide,
4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]methanesulfonamide,
4'-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carba-
zol-6(1H)-yl)butanoic acid,
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]methanesulfonamide,
6-acetyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione,
3-(4-(2,6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-
-c]carbazol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanenitrile,
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-tetrazol-5-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl))-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfanyl)ethyl]pyrrol-
o[3,4-c]carbazole-1,3(2H,6H)-dione,
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]benzenesulfonamide,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfonyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfinyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-tetrazol-5-yl)ethyl]pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione,
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanamide,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfonyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione,
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanoic acid,
4-(2-chlorophenyl)-6-(2,3-dihydroxypropyl)-9-hydroxypyrrolo[3,4-c]carbazo-
le-1,3(2H, 6H)-dione,
2-(4-(2,6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]ca-
rbazol-6(1H)-yl)ethylmethanesulfonate,
4-(2-chlorophenyl)-9-hydroxy-6-[2-(4H-1,2,4-triazol-3-ylsulfanyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
9-hydroxy-6-(2-hydroxyethyl)-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, 6-(3-bromopropyl)-4-(2,
6-dichlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-(3-methoxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-(2-hydroxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[(2S)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(1H-imidazol-5-yl)ethyl]propanamide,
9-hydroxy-6-(3-hydroxypropyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole--
1,3(2H,6H)-dione, methyl
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoate,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(4-morpholinyl)ethyl]propanamide,
4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl]butanenitrile,
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]ca-
rbazole-1,3(2H,6H)-dione,
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide,
4-(2-chlorophenyl)-6-(3,4-dihydroxybutyl)-9-hydroxypyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione,
3-(4-(2-chloro-6-methoxyphenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,-
4-c]carbazol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide,
4-(2-chlorophenyl)-9-hydroxy-6-[(2R)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione,
2-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)ethylmethanesulfonate,
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione,
9-hydroxy-6-(2-hydroxyethyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione,
4-(2-chlorophenyl)-6-(2-hydroxyethyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,-
3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[3-(methylsulfanyl)propylpyrrolo[3,4-c]car-
bazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-6-ethyl-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-di-
one,
4-(2-chlorophenyl)-9-hydroxy-6-isopropylpyrrolo[3,4-c]carbazole-1,3(2-
H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione,
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-[3-(4-morpholinyl)propyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione,
6-(2-chloroethyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione,
6-(3-bromopropyl)-4-(2-chloro-6-methoxyphenyl)-9-hydroxypyrrolo[3,4-c]car-
bazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(methylamino)propyl]pyrrolo[3-
,4-c]carbazole-1,3(2H,6H)-dione,
4-(2-chlorophenyl)-9-hydroxy-6-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione,
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(4-morpholinyl)propyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, or
4-(2,6-dichlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,-
4-c]carbazole-1,3(2H,6H)-dione.
9. The pharmaceutical composition according to any one of claims 1
to 6, wherein the M-phase promoter is a Chk1 inhibitor, an Hsp90
inhibitor, or a Myt1 inhibitor.
10. The pharmaceutical composition according to claim 9, wherein
the Chk1 inhibitor is SCH900776, UCN-01, GDC-0425, XL844, CEP-3891,
CHIR-124, CHIR-600, PF-00394691, PF-00477736,
N-aryl-N'-pyrazinylurea, Go6976, SB-218078, ICP-1, PD-0166285,
CBP-501, staurosporine, isogranulatimide, debromohymenialdisine
(DBH), scytonemin, pyrimidine, pyrrolopyrimidine,
pyrazolopyrimidine, furanopyrimidine, pyrazoloquinoline,
imidazopyrazine, pyrimidinylindazolylamine, 2-ureidothiophene,
3-ureidothiophene, triazolone, diarylurea, benzimidazole quinolone,
dibenzodiazepinone, indolinone, aminopyrazole, indenopyrazole, or
diazepinoindolone.
11. The pharmaceutical composition according to claim 9, wherein
the Hsp90 inhibitor is geldanamycin, tanespimycin (17-AAG),
17-aminodemethoxygeldanamycin (IPI-493),
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG),
XL888, SNX-2112, SNX-5422, SNX-7081, ganetespib (STA-9090),
AT13387, AUY922, Debio0932, BIIB028, BIIBO21, MPC-3100, MPC-0767,
retaspimycin (IPI-504), PU3, PU24FCI, PU-H58, PU-H71, DS-2248,
KW-2478, CCT018159, CCT0129397, BJ-B11, elesclomol (STA-4783),
G3130, gedunin, herbimycin, radester, KNK437, HSP990, or
NVP-BEP800.
12. The pharmaceutical composition according to claim 9, wherein
the Myt1 inhibitor is
2-(4-fluorophenylamino)-4-(4-pyridyl)thiazole,
2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole,
3-(3,4-dichlorophenyl)-5-[4-[2-[(2-pyridyl)amino]thiazolyl]]-isoxazole,
3-(3,4-dichlorophenyl)-5-[4-[2-(3-pyridyl)amino]thiazolyl]-isoxazole,
1,4-bis(2-phenylamino-4-thiazolyl)benzene,
1,4-bis(2-phenylamino-4-thiazolyl)benzene dihydrobromide,
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene,
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene
dihydrobromide, 1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene,
1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene dihydrobromide,
1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene,
1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene bistrifluoroacetate,
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino)-4-thi-
azolyl]benzene,
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino)-4-thi-
azolyl]benzene bistrifluoroacetate,
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene,
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene,
1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene,
1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
4,4'-di(2,2-phenylaminothiazolyl),
4,4'-di(2,2-phenylaminothiazolyl) dihydrobromide,
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl),
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl) bistrifluoroacetate,
4,4'-di(2-(2-pyridyl)aminothiazolyl),
4,4'-di(2-(2-pyridyl)aminothiazolyl) bistrifluoroacetate,
bis[2-(4-phenyl-5-methyl)thiazolyl]amine,
bis[2-(4-phenyl-5-methyl)thiazolyl]amine hydrobromide,
bis[2-(4-(2-pyridyl)thiazolyl]amine,
bis[2-(4-(2-pyridyl)thiazolyl]amine dihydrobromide,
bis[2-[4-(3-pyridyl)thiazolyl)amine,
bis[2-[4-(3-pyridyl)thiazolyl)amine bistrifluoroacetate,
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine,
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine dihydrobromide,
1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene,
1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene dihydrobromide, or
dasatinib.
13. An anticancer composition comprising a pharmaceutical
composition according to any one of claims 1 to 12.
14. A therapeutic drug for cancer comprising a Cdc7 inhibitor and
an M-phase promoter in combination.
15. The therapeutic drug for cancer according to claim 14, wherein
the therapeutic drug for cancer is a combination drug.
16. The therapeutic drug for cancer according to claim 14, wherein
the therapeutic drug for cancer is a kit comprising a drug
containing the Cdc7 inhibitor and a drug containing the M-phase
promoter.
Description
TECHNICAL FIELD
[0001] The present invention relates to an anticancer composition.
More specifically, the present invention relates to an anticancer
composition comprising a Cdc7 inhibitor and an M-phase promoter in
combination.
BACKGROUND ART
[0002] Cancer is a disease that is caused by the non-limiting
growth of cells which have lost the control of the cell cycle.
Since cancer cells generally grow faster than normal cells, it is
considered that cancer can be treated by the control of cell
division and DNA replication. In fact, gemcitabine having a DNA
replication inhibitory effect is widely used in the treatment of
non-small cell lung cancer, pancreatic cancer, bile duct cancer,
urinary bladder cancer, breast cancer, or ovary cancer, etc.
[0003] Various proteins are involved in the process of the cell
cycle. In general, the biological functions of proteins are
regulated by various mechanisms of post-translational
modifications. Specifically, methylation, acetylation,
glycosylation, phosphorylation, and the like are involved in the
functional or structural modifications of proteins. Among these
post-translational modifications, the phosphorylation is an
important mechanism related to the regulation of many functions
such as intracellular signal transduction, cell cycle, and cell
death. For example, 1/3 or more of the intracellular proteins of
mammalian cells are deemed to be phosphorylated.
[0004] Protein kinases are enzymes that catalyze the reaction of
bonding a phosphoric acid group to a particular amino acid residue
in their substrate proteins. This action of the protein kinases
phosphorylates a protein at a particular phosphorylation site. The
protein kinases are classified as follows on the basis of the types
of amino acids at sites to be phosphorylated:
[0005] serine-threonine kinase (which phosphorylates a Ser/S or
Thr/T residue) and
[0006] tyrosine kinase (which phosphorylates Tyr/Y)
[0007] Cdc7, a serine-threonine kinase, is an essential protein
kinase that participates in the initiation of DNA replication in
the cell cycle. Cdc7 forms a complex with a cofactor, such as Dbf4
(ASK), which activates its phosphorylating effect, and
phosphorylates a substrate MCM (minichromosome maintenance)
protein. This phosphorylation appears to allow Cdc45 and DNA
polymerase to assemble on DNA so that an MCM complex is formed to
start DNA replication (see Non-Patent Document 1).
[0008] In recent years, Cdc7 has received attention as a target of
anticancer agents and has been actively studied. For example, Cdc7
has been found to be overexpressed not only in general human
tumor-derived cell lines but in cancer cells, such as breast
cancer, colon cancer, and lung cancer cells, collected from
organisms (see Non-Patent Document 2). Particularly, it has
recently been shown that Cdc7 is overexpressed in triple negative
(ER-/PR-/Her2-) breast cancer cells having p53 mutation (see
Non-Patent Document 3). Cdc7 is thus expected to serve as a
promising target for triple negative-type breast cancer, which has
been regarded as being difficult to treat. In fact, a Cdc7
expression suppression experiment using an RNA interference
technique has demonstrated that the inhibition of Cdc7 expression
induces the arrest of the cell cycle of normal cells. More
importantly, the inhibition of Cdc7 based on the RNA interference
technique inhibited the growth of human tumor cells such as HeLa
and HCT116, but was less effective for inhibiting normal cells
(normal human skin fibroblasts) (see Non-Patent Document 4).
[0009] The deletion of DNA replication factors often brings about
cell death to cancer cells. Since Cdc7 is also an essential protein
kinase involved in the initiation of DNA replication in the cell
cycle, its deletion induces the death of cancer cells, regardless
of the status of the p53 gene that controls the suppression of the
cell growth cycle involving intracellular DNA repair, cell growth
arrest, apoptosis, etc. Masai et al. have utilized a fluorescent
probe of recently developed Fucci (fluorescent ubiquitination-based
cell cycle indicator) to study cell death induced by the deletion
of Cdc7 while observing the progression of the cell cycle at real
time (see Non-Patent Document 5). They have showed that the
inhibition of Cdc7 induces clear cell cycle response in both of
p53-positive and p53-negative cells. Particularly, in the
p53-negative cells, the progression of the cell cycle is
temporarily arrested in the G2-phase prior to the M-phase so that
cyclin B1 and other mitotic control gene products accumulate.
Subsequently, the G2-phase proceeds to the abnormal M-phase, and
cell death occurs after the mitosis. On the other hand, in the
p53-positive cancer cells, cyclin B1 does not accumulate, whereas
most of the cancer cells are reportedly killed by transition to the
abnormal S-phase after the deletion of Cdc7 (see Non-Patent
Document 5).
[0010] Thus, inhibitors that selectively inhibit Cdc7 are expected
to exhibit an effective therapeutic effect on various cancers.
Various compounds having a Cdc7 inhibitory effect have been
reported so far (see Patent Document 1). Particularly, furanone
derivatives having a Cdc7 inhibitory effect have been reported (see
Patent Document 2).
[0011] Wee1 is a nuclear protein kinase that belongs to protein
kinases of the serine-threonine family and plays a role as a
regulator important for the progression of the cell cycle together
with a dephosphorylating enzyme Cdc25.
[0012] The Wee1 kinase suppresses the activity of Cdkl kinase
through the phosphorylation of its Tyr14 and Tyr15, whereas Cdc25
dephosphorylates and activates these tyrosine residues. Wee1 or
Cdc25 undergoes activation or suppression by the G2/M checkpoint
mechanisms. Specifically, the transition from the G2-phase to the
M-phase is controlled by the balance between the functions of these
enzymes Wee1 and Cdc25 located downstream of the checkpoint.
[0013] From the aforementioned functions of Wee1, it is considered
that the inhibition of Wee1 can cause the transition of abnormal or
defective cells to the M-phase, leading to immature mitosis or cell
death. The application of Wee1 inhibitors to anticancer treatment
has therefore been deliberated. In fact, a Wee1 inhibitor MK-1775
has been reported to have an anticancer effect (see Non-Patent
Document 6). Its anticancer effect or selectivity for cancer cells,
however, is less than satisfactory.
[0014] On the other hand, a Wee1 inhibitor MK-1775 developed by
Merck KGaA has been reported to enhance the cytotoxic effect of a
DNA-damaging agent such as gemcitabine on human sarcoma (Non-Patent
Document 7). Unlike the DNA-damaging agent such as gemcitabine,
Cdc7 inhibitors do not directly cause DNA damage. Hence, no
conventional technique has disclosed the combination of a Cdc7
inhibitor and a Wee1 inhibitor or reported its anticancer effect on
cancer cells or cancer cell selectivity.
PRIOR ART DOCUMENTS
Patent Documents
[0015] [Patent Document 1] International Publication No. WO
2008/046982 [0016] [Patent Document 2] International Publication
No. WO 2012/133802
Non-Patent Document
[0016] [0017] [Non-Patent Document 1] H. Masai et al., Journal of
Cellular Physiology, 190, 2002, 287-296 [0018] [Non-Patent Document
2] D. Bonte et al., Neoplasia, 10, 2008, 920-931 [0019] [Non-Patent
Document 3] S. Rodriguez-Acebes et al., The American Journal of
Pathology, 177, 2010, 2034-2045 [0020] [Non-Patent Document 4] A.
Montagnoli et al., Cancer Research, 64, 2004, 7110-7116 [0021]
[Non-Patent Document 5] Masai et al., PLoS One (2012), 7 (5),
e36372 [0022] [Non-Patent Document 6] A. D. Guertin et al.,
Molecular Cancer Therapeutics (2013), 12 (8), 1442-1452 [0023]
[Non-Patent Document 7] J. M. Kreahling et al., PLoS One (2013), 8
(3), e57523
SUMMARY OF INVENTION
Problems to be Solved by the Invention
[0024] An object of the present invention is to provide an
anticancer composition (combination drug) that induces cell death
selectively and specifically for only cancer cells through the
control of DNA replication and cell cycle checkpoint
mechanisms.
Means of Solving the Problems
[0025] The present invention relates to an anticancer composition
comprising a Cdc7 inhibitor and an M-phase promoter in combination.
More specifically, the present invention relates to the
following:
[0026] (1) A pharmaceutical composition comprising a Cdc7 inhibitor
and an M-phase promoter.
[0027] (2) The pharmaceutical composition according to (1), wherein
the Cdc7 inhibitor is a furanone derivative represented by the
following formula (I):
##STR00001##
wherein A represents --COOR1 or a hydrogen atom; R1 represents a
hydrogen atom, a hydrocarbon group optionally having a substituent,
or a heterocyclic ring optionally having a substituent; R2 and R3
are the same or different and each represent a hydrogen atom, a
hydrocarbon group optionally having a substituent, a phenyl group
optionally having a substituent, a heterocyclic ring optionally
having a substituent, a heterocyclic fused ring optionally having a
substituent, or an amino group optionally having a substituent, or
R2 and R3 optionally form a heterocyclic ring optionally having a
substituent or a heterocyclic fused ring optionally having a
substituent, together with the nitrogen atom bonded thereto; and R4
represents a hydrogen atom or a halogen atom, provided that when A
represents --COOR1, R2 and R3 do not represent the amino group
optionally having a substituent at the same time, and when A
represents a hydrogen atom, R3 represents a hydrogen atom, or a
pharmaceutically acceptable salt thereof.
[0028] (3) The pharmaceutical composition according to (2), wherein
the A is --COOR1.
[0029] (4) The pharmaceutical composition according to (2), wherein
the A is a hydrogen atom.
[0030] (5) The pharmaceutical composition according to (3), wherein
the furanone derivative has the structure of the following compound
(I-A), compound (I-B), compound (I-C), compound (I-D), or compound
(I-E): [0031] formula (I-A): isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,-
5-dihydrofuran-3-carboxylate
[0031] ##STR00002## [0032] formula (I-B): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(7-methoxy-3,4-dihydroisoq-
uinolin-2(1H)-yl)-4-oxo-4,5-dihydrofuran-3-carboxylate
[0032] ##STR00003## [0033] formula (I-C): isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
[0033] ##STR00004## [0034] formula (I-D): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
[0034] ##STR00005## [0035] and [0036] formula (I-E):
cyclopropylmethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,
5-dihydrofuran-3-carboxylate
##STR00006##
[0037] (6) The pharmaceutical composition according to (1), wherein
the Cdc7 inhibitor is any of the following compounds: [0038]
formula (I-F):
2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone
[0038] ##STR00007## [0039] and [0040] formula (I-G):
5-(2-amino-pyrimidin-4-yl)-2-(2,4-dichloro-phenyl)-1H-pyrrole-3-carboxyli-
c acid amide
##STR00008##
[0041] (7) The pharmaceutical composition according to any one of
(1) to (6), wherein the M-phase promoter is a Wee1 inhibitor.
[0042] (8) The pharmaceutical composition according to (7), wherein
the Wee1 inhibitor is MK-1775
##STR00009## [0043] miR-424, miR-381, [0044]
6-butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-d-
ione, [0045]
9-methoxy-4-(2-methoxy-5-nitrophenyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]c-
arbazole-1,3(2H,3aH)-dione, [0046]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]benzenesulfonamide, [0047]
4-(2,6-dichlorophenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]carbazo-
le-1,3(2H,6H)-dione, [0048]
4-(2,6-dichlorophenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione, [0049]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-(1H)-yl)-N-(1H-tetrazol-5-yl)propanamide, [0050]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfinyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0051]
6-(3-bromopropyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione, [0052]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoic acid, [0053]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]-2-(dimethylamino)ethanesulfonamide,
[0054]
4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
[0055]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,-
4-c]carbazol-6(1H)-yl)propanoyl]methanesulfonamide, [0056]
4'-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carba-
zol-6(1H)-yl)butanoic acid, [0057]
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]methanesulfonamide, [0058]
6-acetyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0059]
3-(4-(2,6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]ca-
rbazol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide, [0060]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanenitrile, [0061]
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-tetrazol-5-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione, [0062]
4-(2-chlorophenyl))-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfanyl)ethyl]pyrrol-
o[3,4-c]carbazole-1,3(2H,6H)-dione, [0063]
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]benzenesulfonamide, [0064]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfonyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0065]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfinyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0066]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-tetrazol-5-yl)ethyl]pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione, [0067]
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanamide, [0068]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfonyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0069]
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanoic acid, [0070]
4-(2-chlorophenyl)-6-(2,3-dihydroxypropyl)-9-hydroxypyrrolo[3,4-c]carbazo-
le-1,3(2H,6H)-dione, [0071]
2-(4-(2,6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]ca-
rbazol-6(1H)-yl)ethylmethanesulfonate, [0072]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(4H-1,2,4-triazol-3-ylsulfanyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0073]
9-hydroxy-6-(2-hydroxyethyl)-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0074]
6-(3-bromopropyl)-4-(2,6-dichlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-
-1,3(2H,6H)-dione, [0075]
4-(2-chlorophenyl)-9-hydroxy-6-(3-methoxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0076]
4-(2-chlorophenyl)-9-hydroxy-6-(2-hydroxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0077]
4-(2-chlorophenyl)-9-hydroxy-6-[(2S)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione, [0078]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, [0079]
9-hydroxy-6-(3-hydroxypropyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole--
1,3(2H,6H)-dione, [0080] methyl
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoate, [0081]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(4-morpholinyl)ethyl]propanamide, [0082]
4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl]butanenitrile, [0083]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]ca-
rbazole-1,3(2H,6H)-dione, [0084]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide, [0085]
4-(2-chlorophenyl)-6-(3,4-dihydroxybutyl)-9-hydroxypyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione, [0086]
3-(4-(2-chloro-6-methoxyphenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,-
4-c]carbazol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide,
[0087]
4-(2-chlorophenyl)-9-hydroxy-6-[(2R)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione, [0088]
2-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)ethylmethanesulfonate, [0089]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione, [0090]
9-hydroxy-6-(2-hydroxyethyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0091]
4-(2-chlorophenyl)-6-(2-hydroxyethyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,-
3(2H,6H)-dione, [0092] 4-(2-chlorophenyl)-9-hydroxy-6-[3-(methyl
sulfanyl)propylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0093]
4-(2-chlorophenyl)-6-ethyl-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-di-
one, [0094]
4-(2-chlorophenyl)-9-hydroxy-6-isopropylpyrrolo[3,4-c]carbazole-1,3(2H,6H-
)-dione, [0095]
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione, [0096]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-[3-(4-morpholinyl)propyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0097]
6-(2-chloroethyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione, [0098]
6-(3-bromopropyl)-4-(2-chloro-6-methoxyphenyl)-9-hydroxypyrrolo[3,4-c]car-
bazole-1,3(2H,6H)-dione, [0099]
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(methylamino)propyl]pyrrolo[3-
,4-c]carbazole-1,3(2H,6H)-dione, [0100]
4-(2-chlorophenyl)-9-hydroxy-6-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0101]
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(4-morpholinyl)propyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, or [0102]
4-(2,6-dichlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,-
4-c]carbazole-1,3(2H,6H)-dione.
[0103] (9) The pharmaceutical composition according to any one of
(1) to (6), wherein the M-phase promoter is a Chk1 inhibitor, an
Hsp90 inhibitor, or a Myt1 inhibitor.
[0104] (10) The pharmaceutical composition according to (9),
wherein the Chk1 inhibitor is SCH900776, UCN-01, GDC-0425, XL844,
CEP-3891, CHIR-124, CHIR-600, PF-00394691, PF-00477736,
N-aryl-N'-pyrazinylurea, Go6976, SB-218078, ICP-1, PD-0166285,
CBP-501, staurosporine, isogranulatimide, debromohymenialdisine
(DBH), scytonemin, pyrimidine, pyrrolopyrimidine,
pyrazolopyrimidine, furanopyrimidine, pyrazoloquinoline,
imidazopyrazine, pyrimidinylindazolylamine, 2-ureidothiophene,
3-ureidothiophene, triazolone, diarylurea, benzimidazole quinolone,
dibenzodiazepinone, indolinone, aminopyrazole, indenopyrazole, or
diazepinoindolone.
[0105] (11) The pharmaceutical composition according to (9),
wherein the Hsp90 inhibitor is geldanamycin, tanespimycin (17-AAG),
17-aminodemethoxygeldanamycin (IPI-493),
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG),
XL888, SNX-2112, SNX-5422, SNX-7081, ganetespib (STA-9090),
AT13387, AUY922, Debio0932, BIIB028, BIIB021, MPC-3100, MPC-0767,
retaspimycin (IPI-504), PU3, PU24FCI, PU-H58, PU-H71, DS-2248,
KW-2478, CCT018159, CCT0129397, BJ-B11, elesclomol (STA-4783),
G3130, gedunin, herbimycin, radester, KNK437, HSP990, or
NVP-BEP800.
[0106] (12) The pharmaceutical composition according to (9),
wherein the Myt1 inhibitor is [0107]
2-(4-fluorophenylamino)-4-(4-pyridyl)thiazole, [0108]
2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole, [0109]
3-(3,4-dichlorophenyl)-5-[4-[2-[(2-pyridyl)amino]thiazolyl]]-isoxazole,
[0110]
3-(3,4-dichlorophenyl)-5-[4-[2-(3-pyridyl)amino]thiazolyl]-isoxazo-
le, [0111] 1,4-bis(2-phenylamino-4-thiazolyl)benzene, [0112]
1,4-bis(2-phenylamino-4-thiazolyl)benzene dihydrobromide, [0113]
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene,
[0114]
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene
dihydrobromide, [0115]
1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene, [0116]
1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene dihydrobromide,
[0117] 1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene, [0118]
1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene bistrifluoroacetate,
[0119]
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino-
)-4-thiazolyl]benzene, [0120]
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino)-4-thi-
azolyl]benzene bistrifluoroacetate, [0121]
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene, [0122]
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0123] 1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene, [0124]
1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0125] 1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene, [0126]
1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0127] 4,4'-di(2,2-phenylaminothiazolyl), [0128]
4,4'-di(2,2-phenylaminothiazolyl) dihydrobromide, [0129]
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl), [0130]
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl) bistrifluoroacetate,
[0131] 4,4'-di(2-(2-pyridyl)aminothiazolyl), [0132]
4,4'-di(2-(2-pyridyl)aminothiazolyl) bistrifluoroacetate, [0133]
bis[2-(4-phenyl-5-methyl)thiazolyl]amine, [0134]
bis[2-(4-phenyl-5-methyl)thiazolyl]amine hydrobromide, [0135]
bis[2-(4-(2-pyridyl)thiazolyl]amine, [0136]
bis[2-(4-(2-pyridyl)thiazolyl]amine dihydrobromide, [0137]
bis[2-[4-(3-pyridyl)thiazolyl)amine, [0138]
bis[2-[4-(3-pyridyl)thiazolyl)amine bistrifluoroacetate, [0139]
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine, [0140]
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine dihydrobromide,
[0141] 1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene, [0142]
1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene dihydrobromide, or
dasatinib.
[0143] (13) An anticancer composition comprising a pharmaceutical
composition according to any one of (1) to (12).
[0144] (14) A therapeutic drug for cancer comprising a Cdc7
inhibitor and an M-phase promoter in combination.
[0145] (15) The therapeutic drug for cancer according to (14),
wherein the therapeutic drug for cancer is a combination drug.
[0146] (16) The therapeutic drug for cancer according to (14),
wherein the therapeutic drug for cancer is a kit comprising a drug
containing the Cdc7 inhibitor and a drug containing the M-phase
promoter.
Effect of the Invention
[0147] The combination of a Cdc7 inhibitor and an M-phase promoter
can bring about cell death more efficiently with higher selectivity
and specificity for a wide range of cancer cells, as compared with
use of the Cdc7 inhibitor or the M-phase promoter alone.
Particularly, the Cdc7 inhibitor can maintain cell survival by
leading cancer cells to cell death while safely arresting the cell
cycle of normal cells. On the other hand, the M-phase promoter
causes the accumulation of DNA damage and the induction of
mitotic-phase cell death by promoting abnormal progression to the
M-phase through the invalidation of the cell cycle checkpoints of
cancer cells. Such an anticancer agent has the new mechanism of
action.
BRIEF DESCRIPTION OF THE DRAWINGS
[0148] FIG. 1 is a diagram of FACS showing the interaction between
compound (I-D) or compound (I-E) as a Cdc7 inhibitor and a Wee1
inhibitor (MK-1775) as an M-phase promoter for colon cancer
cells.
[0149] FIG. 2 is a diagram of FACS showing the interaction between
compound (I-D) or compound (I-E) and a Wee1 inhibitor (MK-1775) for
normal cells.
[0150] FIG. 3 is a diagram of FACS showing the interaction between
compound (I-D) or compound (I-E) and MK-1775 for Panc-1 cells
(pancreatic cancer cell line).
[0151] FIG. 4 is a diagram of FACS showing that a combination drug
of compound (I-D) or compound (I-E) and MK-1775 is effective even
if its composition is changed.
[0152] FIG. 5 is a diagram of FACS showing the interaction between
compound (I-A) as a Cdc7 inhibitor and MK-1775 in combination.
[0153] FIG. 6 is a diagram of FACS showing the interaction between
compound (I-B) as a Cdc7 inhibitor and MK-1775 in combination.
[0154] FIG. 7 is a diagram of FACS showing the interaction between
compound (I-C) as a Cdc7 inhibitor and MK-1775 in combination.
[0155] FIG. 8 is a diagram of FACS showing the interaction between
a Cdc7 inhibitor (compound (I-F) or compound (I-G)) and MK-1775 in
combination.
[0156] FIG. 9 is a diagram of FACS showing the interaction between
a Chk1 inhibitor SCH900776 (SCH) as an M-phase promoter and
compound (I-D) or compound (I-E) in combination.
[0157] FIG. 10 is a diagram of FACS showing the interaction between
a kinase (e.g., Chk1) inhibitor UCN-01 as an M-phase promoter and
compound (I-D) or compound (I-E) in combination.
[0158] FIG. 11 is a diagram of FACS showing the interaction between
an Hsp90 inhibitor geldanamycin as an M-phase promoter and compound
(I-D) or compound (I-E) in combination.
[0159] FIG. 12 is a diagram of the rate of inhibition of cell
growth showing the interaction between compound (I-D) and a Wee1
inhibitor (MK-1775) in combination for human breast cancer cells
(MDA-MB-231).
[0160] FIG. 13 is a diagram of the rate of inhibition of cell
growth showing the interaction between compound (I-E) and a Wee1
inhibitor (MK-1775) in combination for human breast cancer cells
(MDA-MB-231).
[0161] FIG. 14 is a diagram of BLISS scores showing the interaction
between compound (I-D) and a Wee1 inhibitor (MK-1775) in
combination for human breast cancer cells (MDA-MB-231).
[0162] FIG. 15 is a diagram of BLISS scores showing the interaction
between compound (I-E) and a Wee1 inhibitor (MK-1775) in
combination for human breast cancer cells (MDA-MB-231).
DESCRIPTION OF EMBODIMENTS
(1) Cdc7 Inhibitor
[0163] In the present invention, the Cdc7 inhibitor refers to a
drug that inhibits Cdc7 kinase activity and includes drugs
inhibiting Cdc7 kinase, such as low-molecular compounds,
polypeptides, proteins, nucleic acids (siRNA, miRNA, aptamers,
etc.), and other high-molecular compounds.
[0164] The inhibition of Cdc7 allows abnormal DNA replication
specific for cancer cells to proceed to induce cell death. In
normal cells, the normal DNA replication checkpoint mechanism works
to arrest the cell cycle so that the survival thereof can be
maintained. More specifically, Cdc7 causes the phosphorylation of
the MCM protein in a complex before DNA replication and promotes
replication origin firing.
[0165] The inhibition of Cdc7 inhibits replication origin firing
and therefore decreases the replication origin to stall replication
forks, resulting in an incomplete replication state. In the
presence of a cancerous gene mutation that influences the DNA
replication checkpoint, the cell cycle proceeds abnormally so that
DNA damage is induced in the M-phase to cause the accumulation of
the DNA damage. Finally, cell death specific for cancer cells is
induced.
[0166] Examples of the Cdc7 inhibitor include compounds listed in
JP 2013-525354 A, JP 2013-525304 A, JP 2013-525303 A, JP
2013-522212 A, JP 2013-511487 A, JP 2012-533553 A, JP 2012-533551
A, JP 2012-519653 A, JP 2011-507908 A, JP 2010-527324 A, JP
2010-519324 A, JP 2010-505922 A, JP 2009-534400 A, JP 2009-531373 A
(International Publication No. WO 2007/110344), JP 2009-519919 A,
JP 2009-515849 A, JP 2007-501827 A, JP 2007-501825 A, Domestic
Re-publication of PCT International Publication for Patent
Application Nos. 2011/102399 and 2010/122979, and International
Publication Nos. WO 2011/102399, WO 2012/002568, and WO 2012/133802
(Patent Document 2).
[0167] According to one embodiment, the Cdc7 inhibitor is a
furanone derivative represented by the following formula (I):
##STR00010##
wherein A represents --COOR1 or a hydrogen atom; R1 represents a
hydrogen atom, a hydrocarbon group optionally having a substituent,
or a heterocyclic ring optionally having a substituent; R2 and R3
are the same or different and each represent a hydrogen atom, a
hydrocarbon group optionally having a substituent, a phenyl group
optionally having a substituent, a heterocyclic ring optionally
having a substituent, a heterocyclic fused ring optionally having a
substituent, or an amino group optionally having a substituent, or
R2 and R3 optionally form a heterocyclic ring optionally having a
substituent or a heterocyclic fused ring optionally having a
substituent, together with the nitrogen atom bonded thereto; and R4
represents a hydrogen atom or a halogen atom, provided that when A
represents --COOR1, R2 and R3 do not represent the amino group
optionally having a substituent at the same time, and when A
represents a hydrogen atom, R3 represents a hydrogen atom, or a
pharmaceutically acceptable salt thereof, which is described in
International Publication No. WO 2012/133802 (Patent Document
2).
[0168] In the formula (I), examples of the hydrocarbon group
optionally having a substituent include
a) a linear or branched alkyl group having 1 to 6 carbon atoms
(e.g., methyl, ethyl, isopropyl, tert-butyl, and hexyl), b) a
linear or branched alkenyl group having 1 to 6 carbon atoms (e.g.,
vinyl, allyl, isopropenyl, and 2-butenyl), c) an alkynyl group
having 2 to 6 carbon atoms (e.g., ethynyl, propargyl, and
2-butynyl), d) a cycloalkyl group having 3 to 8 carbon atoms (e.g.,
cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl), e) a
cycloalkenyl group having 3 to 8 carbon atoms (e.g., cyclohexenyl
and cycloheptenyl), and f) an aralkyl group whose aryl moiety is
aryl having 6 to 14 carbon atoms (e.g., phenyl, naphthyl, and
indenyl) and whose alkylene moiety is a group in which one hydrogen
atom has been removed from the alkyl group.
[0169] Examples of the heterocyclic moiety of the heterocyclic ring
optionally having a substituent include an alicyclic heterocyclic
group and an aromatic heterocyclic group. Examples of the alicyclic
heterocyclic group include a 3- to 8-membered heterocyclic group
containing at least one heteroatom selected from a nitrogen atom, a
sulfur atom, and an oxygen atom. Specific examples thereof include
pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, and
thiomorpholinyl. Examples of the aromatic heterocyclic group
include a 5- or 6-membered monocyclic aromatic heterocyclic group
containing at least one heteroatom selected from a nitrogen atom, a
sulfur atom, and an oxygen atom. Specific examples thereof include
imidazolyl, pyrazolyl, thienyl, thiazolyl, and pyridyl.
[0170] Examples of the heterocyclic fused ring moiety of the
heterocyclic fused ring optionally having a substituent include a
3- to 8-membered ring-fused bicyclic heterocyclic group containing
at least one heteroatom selected from a nitrogen atom, a sulfur
atom, and an oxygen atom. Specific examples thereof include
benzothiophenyl, benzimidazolyl, indazolyl, benzoxazolyl,
benzothiazolyl, indolyl, isoquinolyl, and phthalimide.
[0171] Examples of the amino group optionally having a substituent
include an amino group having a linear, branched, or cyclic alkyl
group having 1 to 6 carbon atoms, an aryl group, a heteroaryl
group, or the like which is substituted or unsubstituted and
include an amino group bonded to an alkyl group, an alkylamino
group, an aryl group, a heteroaryl group, a heterocyclic group, a
heterocyclic fused ring group, or the like which has one or two or
more substituents or is unsubstituted. The "one or two or more
substituents" in these groups bonded to an amino group may be one
or two or more identical or different arbitrary groups, unless
otherwise specified. Examples thereof include a halogen atom, a
substituted or unsubstituted alkyl group, a substituted or
unsubstituted alkenyl group, a substituted or unsubstituted alkynyl
group, a substituted or unsubstituted alkoxy group, an amino group,
a nitro group, a cyano group, a hydroxy group, a substituted or
unsubstituted alkylamino group, a carbamoyl group, a carboxyl
group, a formyl group, an acetyl group, and a benzoyl group.
[0172] The "substituent" in the hydrocarbon group optionally having
a substituent, the heterocyclic ring optionally having a
substituent, the phenyl group optionally having a substituent, or
the heterocyclic fused ring optionally having a substituent may be
one or two or more arbitrary types of substituents that are located
at arbitrary chemically possible positions, unless otherwise
specified. In the case of two or more substituents, these
substituents may be the same as or different from each other.
Examples thereof include a halogen atom, a substituted or
unsubstituted alkyl group, a substituted or unsubstituted alkoxy
group, a substituted or unsubstituted amino group, a nitro group, a
cyano group, a hydroxy group, a substituted or unsubstituted
alkylamino group, a carbamoyl group, a carboxyl group, a formyl
group, an acetyl group, and a benzoyl group.
[0173] Examples of the heterocyclic group in the heterocyclic ring
optionally having a substituent or the heterocyclic fused ring
optionally having a substituent which is formed by R2 and R3
together with the nitrogen atom bonded thereto include a 3- to
8-membered heterocyclic group containing at least one heteroatom
selected from a nitrogen atom, a sulfur atom, and an oxygen atom or
a 3- to 8-membered ring-fused bicyclic alicyclic heterocyclic group
containing at least one heteroatom selected from a nitrogen atom, a
sulfur atom, and an oxygen atom and specifically include
pyrrolidinyl, piperidyl, morpholinyl, thiomorpholinyl, azepinyl,
diazepinyl, dihydroisoquinolyl, tetrahydroisoquinolyl,
tetrahydroquinolyl, isoindolinyl, indolinyl,
tetrahydrobenzazepinyl, benzazepinyl, benzodiazepinyl,
benzoxazepinyl, and benzothiazepinyl. Examples of the halogen atom
include fluorine, chlorine, and bromine.
[0174] The compound (I) according to the present invention may
include isomers, for example, depending on the types of
substituents. In the present specification, these isomers may be
indicated by only one form of a chemical structure. The present
invention also encompasses all structurally possible isomers
(geometric isomers, optical isomers, tautomers, etc.) and
encompasses isomers alone and mixtures thereof. The present
invention also encompasses these stereoisomers specifically
represented by the formulas (Z)-(I) and (E)-(I) as the compounds
according to the present invention, and mixtures thereof.
##STR00011##
[0175] Examples of the pharmaceutically acceptable salt of the
compound (I) according to the present invention include: salts of
inorganic acids such as hydrochloric acid, sulfuric acid, carbonic
acid, and phosphoric acid; and salts of organic acids such as
formic acid, acetic acid, fumaric acid, maleic acid,
methanesulfonic acid, and p-toluenesulfonic acid. The present
invention also encompasses: salts of alkali metals such as sodium
and potassium; salts of alkaline earth metals such as magnesium and
calcium; salts of organic amines such as lower alkylamine and lower
alcohol amine; salts of basic amino acids such as lysine, arginine,
and ornithine; and other salts such as ammonium salt.
[0176] The compound (I) according to the present invention and the
pharmaceutically acceptable salt thereof can be produced by a
method described in, for example, International Publication No. WO
2012/133802. In the production method described in International
Publication No. WO 2012/133802, the defined groups may vary under
conditions of the implemented method or may be inappropriate for
carrying out the method. In such a case, the compound (I) according
to the present invention and the pharmaceutically acceptable salt
thereof can be readily produced by a method usually used in organic
synthetic chemistry, for example, approaches of the protection and
deprotection of functional groups [T. W. Greene, Protective Groups
in Organic Synthesis 3rd Edition, John Wiley & Sons, Inc.,
1999]. If necessary, the order of reaction steps including the
introduction of substituents may be changed.
[0177] The compound of the formula (I) is preferably a compound
wherein A is --COOR1 or a hydrogen atom and more preferably has the
structure of the following compound (I-A), compound (I-B), compound
(I-C), compound (I-D), or compound (I-E). [0178] formula (I-A):
isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,-
5-dihydrofuran-3-carboxylate
[0178] ##STR00012## [0179] compound (I-B): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(7-methoxy-3,4-dihydroisoq-
uinolin-2(1H)-yl)-4-oxo-4,5-dihydrofuran-3-carboxylate
[0179] ##STR00013## [0180] compound (I-C): isopropyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
[0180] ##STR00014## [0181] compound (I-D): ethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-4-oxo-2-{[4-(2,2,2-trifluoro-
ethyl)piperazinyl]amino}-4,5-dihydrofuran-3-carboxylate
[0181] ##STR00015## [0182] and [0183] compound (I-E):
cyclopropylmethyl
5-[(1H-pyrrolo[2,3-b]pyridin-3-yl)methylene]-2-(morpholinoamino)-4-oxo-4,
5-dihydrofuran-3-carboxylate
##STR00016##
[0184] In this context, the compound (I-A) is a compound of Example
245 in the specification of Patent Document 2: International
Publication No. WO 2012/133802; the compound (I-B) is a compound of
Example 244 in the specification of Patent Document 2:
International Publication No. WO 2012/133802; the compound (I-C) is
a compound of Example 351 in the specification of Patent Document
2: International Publication No. WO 2012/133802; the compound (I-D)
is a compound of Example 246 in Patent Document 2: International
Publication No. WO 2012/133802; and the compound (I-E) is a
compound of Example 347 in Patent Document 2: International
Publication No. WO 2012/133802.
[0185] According to another embodiment, the Cdc7 inhibitor is
compound (I-F):
2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone
(Merck KGaA, catalog No.: 217707-5MGCN, 217707)
##STR00017## [0186] or [0187] compound (I-G):
5-(2-amino-pyrimidin-4-yl)-2-(2,4-dichloro-phenyl)-1H-pyrrole-3-carboxyli-
c acid amide (compound F26 in the specifications of JP 2009-531373
A and International Publication No. WO 2007/110344)
##STR00018##
[0187] (2) M-Phase Promoter
[0188] In the present invention, the M-phase promoter refers to a
drug having the function of promoting the process from the
transition of cells through the G2/M checkpoint of the cell cycle
to the M-phase, which is a mitotic phase.
[0189] The G2/M checkpoint is a checkpoint that controls the
transition from the G2-phase to the M-phase. Upon activation of
this control by DNA damage or the like, the initiation of the
M-phase is inhibited so that the cells remain in the G2-phase. In
response to DNA damage, ATR (ataxia-telangiectasia mutated related)
activated by phosphorylation phosphorylates and activates Chk1.
Subsequently, the active form of Chk1 downregulates the
phosphorylation of Cdc25 and inhibits the dephosphorylation of Cdkl
by the phosphorylated Cdc25. Cdkl is therefore kept in a highly
phosphorylated and inactive state. Thus, the cell cycle of the
cells is arrested without proceeding to the M-phase.
[0190] Thus, in the unphosphorylated state of Cdkl, the transition
of the cells to the M-phase occurs to promote the cell cycle. A
substance that participates in the mechanism of the process from
the G2/M checkpoint of the cell cycle to the transition to the
M-phase and promotes the transition of cells to the M-phase can be
regarded as the M-phase promoter according to the present invention
even if the substance is any of low molecules and high molecules
such as nucleic acids or proteins.
[0191] Examples of the M-phase promoter include a Wee1 inhibitor, a
Chk1 inhibitor, a Myt1 inhibitor, and a Cdc25 activator. Further
examples thereof include an Hsp90 inhibitor (geldanamycin,
Oncogene, 2008; 27: 5567) and a poly(ADP-ribose) glycohydrolase
(PARG) inhibitor (Biochem Biophys Res Commun, 2013; 441: 793; and
Molecules, 2011; 16: 1854), which have not been reported to
participate directly in the G2/M checkpoint, but have been reported
to promote the transition from the G2-phase to the M-phase.
[0192] In this context, Wee1 is a nuclear kinase that belongs to
protein kinases of the Ser/Thr family. Wee1 inhibits Cdkl through
the phosphorylation thereof at Tyr15 and Thr14 sites in the amino
acid sequence. This Cdkl plays an important role in various
cyclin-dependent pathways of cell cycle checkpoints.
[0193] In the G2/M checkpoint, Wee1 phosphorylates Cdkl at Tyr15
and Thr14 so that the kinase activity of the Cdkl is kept low to
hinder the transition to the M-phase (mitosis). On the other hand,
during the transition to the M-phase, the activity of Wee1 is
reduced by some control factors, resulting in enhanced Cdkl
activity.
[0194] The DNA damage checkpoint controls the G2/M transition by
delaying the transition of cells having DNA damage to the M-phase
(mitosis).
[0195] Thus, a drug that inhibits the functions of the Wee1 kinase
(in the present invention, this drug is referred to as a Wee1
inhibitor) promotes the transition of cells to the M-phase via the
G2/M transition. Hence, the Wee1 inhibitor can be a typical example
of the M-phase promoter.
[0196] MK-1775 represented by the following structural formula:
##STR00019##
is a potent and selective Wee1 inhibitor having IC.sub.50 of 5.2 nM
and has the function of masking the DNA damage checkpoint. Its
application to ovary cancer by combined use with a standard
chemical therapy using a DNA-damaging agent has been attempted.
[0197] Examples of the Wee1 inhibitor include miR-424, miR-381, and
[0198]
6-butyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-d-
ione, [0199]
9-methoxy-4-(2-methoxy-5-nitrophenyl)-4,5,6,10c-tetrahydropyrrolo[3,4-c]c-
arbazole-1,3(2H,3aH)-dione, [0200]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]benzenesulfonamide, [0201]
4-(2,6-dichlorophenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]carbazo-
le-1,3(2H,6H)-dione, [0202]
4-(2,6-dichlorophenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione, [0203]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-(1H)-yl)-N-(1 H-tetrazol-5-yl)propanamide, [0204]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfinyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0205]
6-(3-bromopropyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione, [0206]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoic acid, [0207]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)propanoyl]-2-(dimethylamino)ethanesulfonamide,
[0208]
4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione,
[0209]
N-[3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,-
4-c]carbazol-6(1H)-yl)propanoyl]methanesulfonamide, [0210]
4'-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carba-
zol-6(1H)-yl)butanoic acid, [0211]
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]methanesulfonamide, [0212]
6-acetyl-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0213] 3-(4-(2,
6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbazol-6-
(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide, [0214]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanenitrile, [0215]
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-tetrazol-5-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione, [0216]
4-(2-chlorophenyl))-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfanyl)ethyl]pyrrol-
o[3,4-c]carbazole-1,3(2H,6H)-dione, [0217]
N-[4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]car-
bazol-6(1H)-yl)butanoyl]benzenesulfonamide, [0218]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-1,2,4-triazol-5-ylsulfonyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0219]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfinyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0220]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-tetrazol-5-yl)ethyl]pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione, [0221]
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanamide, [0222]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(1H-imidazol-2-ylsulfonyl)ethyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0223]
3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-y-
l)propanoic acid, [0224]
4-(2-chlorophenyl)-6-(2,3-dihydroxypropyl)-9-hydroxypyrrolo[3,4-c]carbazo-
le-1,3(2H,6H)-dione, [0225]
2-(4-(2,6-dichlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]ca-
rbazol-6(1H)-yl)ethylmethanesulfonate, [0226]
4-(2-chlorophenyl)-9-hydroxy-6-[2-(4H-1,2,4-triazol-3-ylsulfanyl)ethyl]py-
rrolo[3,4-c]carbazole-1,3(2H,6H)-dione, [0227]
9-hydroxy-6-(2-hydroxyethyl)-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0228]
6-(3-bromopropyl)-4-(2,6-dichlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-
-1,3(2H,6H)-dione, [0229]
4-(2-chlorophenyl)-9-hydroxy-6-(3-methoxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0230]
4-(2-chlorophenyl)-9-hydroxy-6-(2-hydroxypropyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0231]
4-(2-chlorophenyl)-9-hydroxy-6-[(2S)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione, [0232]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(1H-imidazol-5-yl)ethyl]propanamide, [0233]
9-hydroxy-6-(3-hydroxypropyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole--
1,3(2H,6H)-dione, [0234] methyl
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)propanoate, [0235]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(4-morpholinyl)ethyl]propanamide, [0236]
4-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl]butanenitrile, [0237]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(2-hydroxyethyl)pyrrolo[3,4-c]ca-
rbazole-1,3(2H,6H)-dione, [0238]
3-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide, [0239]
4-(2-chlorophenyl)-6-(3,4-dihydroxybutyl)-9-hydroxypyrrolo[3,4-c]carbazol-
e-1,3(2H,6H)-dione, [0240]
3-(4-(2-chloro-6-methoxyphenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,-
4-c]carbazol-6(1H)-yl)-N-[2-(dimethylamino)ethyl]propanamide,
[0241]
4-(2-chlorophenyl)-9-hydroxy-6-[(2R)-3-hydroxy-2-methylpropyl]pyrrolo[3,4-
-c]carbazole-1,3(2H,6H)-dione, [0242]
2-(4-(2-chlorophenyl)-9-hydroxy-1,3-dioxo-2,3-dihydropyrrolo[3,4-c]carbaz-
ol-6(1H)-yl)ethylmethanesulfonate, [0243]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-(3-hydroxypropyl)pyrrolo[3,4-c]c-
arbazole-1,3(2H,6H)-dione, [0244]
9-hydroxy-6-(2-hydroxyethyl)-4-(2-methoxyphenyl)pyrrolo[3,4-c]carbazole-1-
,3(2H,6H)-dione, [0245]
4-(2-chlorophenyl)-6-(2-hydroxyethyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,-
3(2H,6H)-dione, [0246]
4-(2-chlorophenyl)-9-hydroxy-6-[3-(methylsulfanyl)propylpyrrolo[3,4-c]car-
bazole-1,3(2H,6H)-dione, [0247]
4-(2-chlorophenyl)-6-ethyl-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-di-
one, [0248]
4-(2-chlorophenyl)-9-hydroxy-6-isopropylpyrrolo[3,4-c]carbazole-1,3(2H,6H-
)-dione, [0249]
4-(2-chlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,4-c]-
carbazole-1,3(2H,6H)-dione, [0250]
4-(2-chloro-6-methoxyphenyl)-9-hydroxy-6-[3-(4-morpholinyl)propyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, [0251]
6-(2-chloroethyl)-4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-
(2H,6H)-dione, [0252]
6-(3-bromopropyl)-4-(2-chloro-6-methoxyphenyl)-9-hydroxypyrrolo[3,4-c]car-
bazole-1,3(2H,6H)-dione, [0253]
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(methylamino)propyl]pyrrolo[3-
,4-c]carbazole-1,3(2H,6H)-dione, [0254]
4-(2-chlorophenyl)-9-hydroxy-6-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-d-
ione, [0255]
4-(2-chlorophenyl)-9-hydroxy-6-[2-hydroxy-3-(4-morpholinyl)propyl]pyrrolo-
[3,4-c]carbazole-1,3(2H,6H)-dione, and [0256]
4-(2,6-dichlorophenyl)-9-hydroxy-6-[3-(1H-imidazol-1-yl)propyl]pyrrolo[3,-
4-c]carbazole-1,3(2H,6H)-dione described in the specification of JP
2006-504632 A.
[0257] Examples of the Chk1 inhibitor include a kinase (e.g., Chk1)
inhibitor UCN-01, a Chk1 inhibitor SCH900776, GDC-0425, XL844,
CEP-3891, CHIR-124, CHIR-600, PF-00394691, PF-00477736,
N-aryl-N'-pyrazinylurea, Go6976, SB-218078, ICP-1, PD-0166285,
CBP-501, staurosporine, isogranulatimide, debromohymenialdisine
(DBH), scytonemin, pyrimidine, pyrrolopyrimidine,
pyrazolopyrimidine, furanopyrimidine, pyrazoloquinoline,
imidazopyrazine, pyrimidinylindazolylamine, 2-ureidothiophene,
3-ureidothiophene, triazolone, diarylurea, benzimidazole quinolone,
dibenzodiazepinone, indolinone, aminopyrazole, indenopyrazole, and
diazepinoindolone.
[0258] Examples of the Hsp90 inhibitor include geldanamycin,
tanespimycin (17-AAG), 17-aminodemethoxygeldanamycin (IPI-493),
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG),
XL888, SNX-2112, SNX-5422, SNX-7081, ganetespib (STA-9090),
AT13387, AUY922, Debio0932, BIIB028, BIIBO21, MPC-3100, MPC-0767,
retaspimycin (IPI-504), PU3, PU24FCI, PU-H58, PU-H71, DS-2248,
KW-2478, CCT018159, CCT0129397, BJ-B11, elesclomol (STA-4783),
G3130, gedunin, herbimycin, radester, KNK437, HSP990, and
NVP-BEP800.
[0259] Examples of the Myt1 inhibitor include: [0260]
2-(4-fluorophenylamino)-4-(4-pyridyl)thiazole, [0261]
2-(4-fluorophenylamino)-4-(4-fluorophenyl)thiazole, [0262]
3-(3,4-dichlorophenyl)-5-[4-[2-[(2-pyridyl)amino]thiazolyl]]-isoxazole,
and [0263]
3-(3,4-dichlorophenyl)-5-[4-[2-(3-pyridyl)amino]thiazolyl]-isoxazole,
[0264] which are compounds described in JP 2002-531500 A; [0265]
1,4-bis(2-phenylamino-4-thiazolyl)benzene, [0266]
1,4-bis(2-phenylamino-4-thiazolyl)benzene dihydrobromide, [0267]
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene,
[0268]
1-[2-phenyl-4-(5-bromo)thiazolyl]-4-[2-phenyl-4-thiazolyl]benzene
dihydrobromide, [0269]
1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene, [0270]
1,4-bis(2-phenyl)-(4-(5-bromo)thiazolylbenzene dihydrobromide,
[0271] 1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene, [0272]
1,4-bis(2-(3-pyridylamino)-4-thiazolyl)benzene bistrifluoroacetate,
[0273]
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino-
)-4-thiazolyl]benzene, [0274]
1-[(2-(3-pyridylamino)-4-(5-bromo)thiazolyl)]-4-[2-(3-pyridylamino)-4-thi-
azolyl]benzene [0275] bistrifluoroacetate, [0276]
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene, [0277]
1,3-bis(2-(3-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0278] 1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene, [0279]
1,4-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0280] 1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene, [0281]
1,3-bis(2-(2-pyridylamino)-4-thiazolyl)benzene dihydrobromide,
[0282] 4,4'-di(2,2-phenylaminothiazolyl), [0283]
4,4'-di(2,2-phenylaminothiazolyl) dihydrobromide, [0284]
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl), [0285]
4,4'-di(2-(2-methoxypyrid-5-ylamino)thiazolyl) bistrifluoroacetate,
[0286] 4,4'-di(2-(2-pyridyl)aminothiazolyl), and [0287]
4,4'-di(2-(2-pyridyl)aminothiazolyl) bistrifluoroacetate, [0288]
which are compounds described in JP 2002-531503 A; [0289]
bis[2-(4-phenyl-5-methyl)thiazolyl]amine, [0290]
bis[2-(4-phenyl-5-methyl)thiazolyl]amine hydrobromide, [0291]
bis[2-(4-(2-pyridyl)thiazolyl]amine, [0292]
bis[2-(4-(2-pyridyl)thiazolyl]amine dihydrobromide, [0293]
bis[2-[4-(3-pyridyl)thiazolyl)amine, [0294]
bis[2-[4-(3-pyridyl)thiazolyl)amine bistrifluoroacetate, [0295]
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine, [0296]
N,N-bis(5(3,4-dichlorophenyl)-2-thiazolyl)amine dihydrobromide,
[0297] 1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene, and [0298]
1,3-bis[4-(3-pyridyl)-2-thiazolylamino]benzene dihydrobromide,
[0299] which are compounds described in JP 2002-531504 A; and
[0300] dasatinib.
[0301] The compound (I) according to the present invention or the
pharmaceutically acceptable salt thereof can be used as a
pharmaceutical drug, particularly, an antitumor agent, in the form
of a conventional pharmaceutical preparation for oral
administration or parenteral administration such as
instillation.
[0302] The preparation for oral administration includes: solid
preparations such as tablets, granules, powders, and capsules; and
liquid preparations such as syrups. These preparations can be
prepared by conventional methods. The solid preparations can be
prepared by using conventional pharmaceutical carriers such as
lactose, starch (e.g., corn starch), crystalline cellulose (e.g.,
microcrystalline cellulose), hydroxypropylcellulose, calcium
carboxymethylcellulose, talc, and magnesium stearate. The capsules
can be prepared by the encapsulation of the granules or the powders
thus prepared. The syrups can be prepared by the dissolution or
suspension of the compound (I) according to the present invention
or the pharmaceutically acceptable salt thereof in an aqueous
solution containing sucrose, carboxymethylcellulose, or the
like.
[0303] The preparation for parenteral administration includes
injections for instillation. The injection preparations can also be
prepared by a conventional method and can be appropriately
incorporated into a tonicity agent (e.g., mannitol, sodium
chloride, glucose, sorbitol, glycerol, xylitol, fructose, maltose,
and mannose), a stabilizer (e.g., sodium sulfide and albumin), and
an antiseptic (e.g., benzyl alcohol and methyl
p-hydroxybenzoate).
[0304] The compound (I) according to the present invention or the
pharmaceutically acceptable salt thereof is pharmaceutically
effective and is particularly effective for the treatment of tumor.
Examples of the tumor include: solid tumors such as breast cancer,
colon cancer, and lung cancer; and blood cancers such as leukemia,
lymphoma, and myeloma.
[0305] The compound (I) according to the present invention or the
pharmaceutically acceptable salt thereof is effective for
suppressing a wide range of cancer types.
[0306] The dose of the compound (I) according to the present
invention or the pharmaceutically acceptable salt thereof can vary
according to the severity of a disease, the age and body weight of
a patient, a dosage form, etc. The daily dose in an adult is
usually in the range of 1 mg to 1,000 mg, which can be administered
in one portion or in two or three divided potions through an oral
route or a parenteral route.
[0307] The ratio between the Cdc7 inhibitor and the M-phase
promoter in the pharmaceutical composition of the present invention
is 1:300 to 10:1, preferably 1:100 to 3:1, more preferably 1:30 to
1.2:1.
EXAMPLES
Interaction Between Cdc7 Inhibitor and M-Phase Promoter (Wee1
Inhibitor)
[0308] In order to examine the synergistic effect of a Cdc7
inhibitor and an M-phase promoter, a Wee1 inhibitor MK-1775 was
coadministered with the Cdc7 inhibitor (compound I-D or compound
I-E).
[0309] The present inventor had previously demonstrated that the
cytotoxicity of a particular Cdc7 inhibitor to Colo205 is decreased
by its coadministration with paclitaxel, and confirmed that a
compound, such as paclitaxel, which inhibits the G2/M-phase, cannot
be used in a favorable concomitant drug with a particular Cdc7
inhibitor. Accordingly, the influence of the Wee1 inhibitor MK-1775
and the Cdc7 inhibitor in combination on the viability of Colo205
was studied.
Cultured Cells
[0310] COL0205 (RCB2127, RIKEN BRC) was cultured in a 10-cm dish
using an RPMI-1640 medium (Sigma-Aldrich Corp., R8758) supplemented
with 10% FCS (Equitech-Bio, Inc.) and 5% penicillin-streptomycin
(GIBCO/Thermo Fisher Scientific, Inc., 15140). The medium was
removed from the cells in a well grown state (70 to 90% confluent),
and the cells were dissociated from the dish by treatment with 2 mL
of trypsin (TrypL Express, manufactured by GIBCO/Thermo Fisher
Scientific, Inc.) and recovered into the same medium as above.
[0311] Panc-1 (ATCC, CRL-1469) was cultured in a 10-cm dish using a
D-MEM medium (Sigma-Aldrich Corp., D5796) supplemented with 10% FCS
(Equitech-Bio, Inc.) and 5% penicillin-streptomycin (GIBCO/Thermo
Fisher Scientific, Inc., 15140). The medium was removed from the
cells in a well grown state (70 to 90% confluent), and the cells
were dissociated from the dish by treatment with 2 mL of trypsin
(TrypL Express, manufactured by GIBCO/Thermo Fisher Scientific,
Inc.) and recovered into the same medium as above.
[0312] NHDF cells (Cryo NHDF-NeoCC-2509, manufactured by Sanko
Junyaku Co., Ltd.) were cultured in a 10-cm dish using a medium
(Brett Kit FGM2, CLCC-3132). The medium was removed from the NHDF
cells in a well grown state (70 to 90% confluent), and the cells
were washed with 5 mL of HEPES-buffered saline in a subculture
reagent set (CLCC-5034, manufactured by Sanko Junyaku Co.,
Ltd.).
[0313] After removal of the HEPES-buffered saline, the whole dish
was covered with 3 mL of a trypsin/EDTA solution included in the
set. The cells were dissociated from the dish by giving a small
impact on the side of the dish with taps of a hand. Then, 3 mL of a
trypsin-neutralizing solution included in the set was added to the
cells, which were then recovered.
Addition of Compounds to Cultured Cells
[0314] The recovered cells of each line were seeded at
2.5.times.10.sup.5 cells/ml/well to a 6-well plate (BD Falcon,
catalog No. 353046). The cells were cultured overnight in a 5%
CO.sub.2 incubator. On the next day, 500 .mu.l of a medium
supplemented with 1.5 .mu.l of a stock solution having a 1000-fold
concentration of each compound to be added was added to each well,
and the cells were further cultured for 48 to 72 hours under
conditions involving a final concentration of 1 M.
Study on Influence on Cell Cycle
[0315] After the reaction of the cells with the compound for 48 to
72 hours, the cells were dissociated from the well by treatment
with trypsin (TrypL Express, manufactured by GIBCO/Thermo Fisher
Scientific, Inc.) and washed with DPBS. Then, 1 ml of cold ethanol
was added thereto, and the cells were stored at -30.degree. C.
until staining. The cells were washed with DPBS once before
staining and left standing with a propidium iodide (PI) solution at
room temperature for 30 minutes or longer in the dark. The cells
stained with PI were studied for the cell cycle and the rate of
cell death indicated by SubG1 using FACS.
[0316] First, the concentration of MK-1775 was examined for the
upregulation of phosphorylated histone H3. Subsequently, the Cdc7
inhibitor and MK-1775 were added within the concentration range
that would promote the M-phase to the cultures of the colon cancer
cells Colo205 cells.
Evaluation of Synergistic Effect of Drugs Used in Combination Using
BLISS Score
[0317] The BLISS scoring is a criterion often used in the
evaluation of the synergistic effect of drugs used in combination
(Borisy et al., Proc. Natl. Acad. Sci. USA. 100 (13): 7977-7982
(2003); and Buck et al., Mol. Cancer. Ther. 5 (11) (2006)). This
BLISS scoring was used to analyze the effect of the Cdc7 inhibitor
and the Wee1 inhibitor used in combination on the inhibition of
cancer cell growth.
Example 1
Interaction Between Compound (I-D) or Compound (I-E) as Cdc7
Inhibitor and Wee1 Inhibitor as M-Phase Promoter in Combination
[0318] Specifically, 0.1 .mu.M of compound (I-D) was coadministered
with DMSO (control) or 0.25 .mu.M, 0.5 .mu.M, and 0.75 .mu.M each
of the Wee1 inhibitor MK-1775 to Colo205 cells, and the number of
cells that died was examined. Also, 0.1 .mu.M of compound (I-E) was
coadministered with DMSO (control) or each concentration of MK-1775
to the cells, and the number of cells that died was examined. The
results are shown in FIG. 1.
[0319] The cell death induced by compound (I-D) or compound (I-E)
was found to be synergistically increased by the coadministration
with the Wee1 inhibitor.
[0320] MK-1775 in the concentration range of 0.1 to 1 .mu.M
efficiency increased the proportion of cells in the M-phase.
Actually, synergistic increase was observed in the ratio of the
killed cells to the cells treated with MK-1775 and compound (I-D)
or compound (I-E) in combination.
Example 2
Cancer Cell Selectivity of Interaction Between Compound (I-D) or
Compound (I-E) and MK-1775 (Wee1 Inhibitor)
[0321] In order to examine whether the synergistic effect of
compound (I-D) or compound (I-E) and MK-1775 (Wee1 inhibitor) would
be observed in normal cells, normal human skin fibroblast (NHDF)
cells were treated with the combination drug and examined.
[0322] The NHDF cells were treated with compound (I-D) or compound
(I-E) and varying concentrations of MK-1775 in combination.
[0323] Specifically, 0.1 .mu.M of compound (I-D) was coadministered
with DMSO (control) or 0.25 .mu.M, 0.5 .mu.M, and 0.75 .mu.M each
of MK-1775 to NHDF cells, and the number of cells that died was
examined. Also, 0.1 .mu.M of compound (I-E) was coadministered with
DMSO (control) or each concentration of MK-1775 to the cells, and
the number of cells that died was examined. The results are shown
in FIG. 2.
[0324] The examination of compound (I-D) or compound (I-E) at a
concentration of 0.1 M showed no increase in cytotoxicity to the
NHDF cells as normal cells even supplemented with the Wee1
inhibitor MK-1775, demonstrating that the effect brought about by
the combination of compound (I-D) or compound (I-E) and MK-1775 is
selective for cancer cells.
Example 3
Interaction Between Compound (I-D) or Compound (I-E) and MK-1775 in
Panc-1 Cells (Pancreatic Cancer Cell Line)
[0325] Specifically, 0.1 .mu.M of compound (I-D) was coadministered
with DMSO (control) or 0.5 .mu.M and 0.75 .mu.M each of MK-1775 to
pancreatic cancer cell line Panc-1 cells, and the number of cells
that died was examined. Also, 0.1 .mu.M of compound (I-E) was
coadministered with DMSO (control) or each concentration of MK-1775
to the cells, and the number of cells that died was examined. The
results are shown in FIG. 3. The cell death of the Panc-1 cells
(pancreatic cancer cell line) induced by compound (I-D) or compound
(I-E) was also found to be synergistically increased by the
coadministration with the Wee1 inhibitor.
Example 4
Variation in Effect Depending on Composition of Compound (I-D) or
Compound (I-E) and MK-1775 in Combination Drug
[0326] While the composition (ratio by .mu.M) of compound (I-E) and
MK-1775 in the combination drug was changed within the range of
1:100 to 3:1, such as 0.01:1.0, 0.03:0.1, and 0.3:0.1, compound
(I-E) and MK-1775 were coadministered to Colo205 cells, and the
number of cells that died was examined. The results are shown in
FIG. 4. In the range of compound (I-E):MK-1775=1:100 to 3:1, the
cell death induced by compound (I-E) was found to be sufficiently
synergistically increased by the coadministration with the Wee1
inhibitor.
Example 5
Interaction Between Compound (I-A) and MK-1775 in Combination
[0327] A Cdc7 inhibitor was coadministered with MK-1775 to Colo205
cells, and the number of cells that died was examined, in the same
way as in Example 1 except that compound (I-A) was used as the Cdc7
inhibitor. The results are shown in FIG. 5. Even when compound
(I-A) was used as a different Cdc7 inhibitor, the induced cell
death was found to be synergistically increased by the
coadministration with the Wee1 inhibitor MK-1775.
Example 6
Interaction Between Compound (I-B) and MK-1775 in Combination
[0328] A Cdc7 inhibitor was coadministered with MK-1775 to Colo205
cells, and the number of cells that died was examined, in the same
way as in Example 1 except that compound (I-B) was used as the Cdc7
inhibitor, and the concentration of compound (I-B) was set to 0.3
.mu.M. The results are shown in FIG. 6. Even when compound (I-B)
was used as a different Cdc7 inhibitor, the induced cell death was
found to be synergistically increased by the coadministration with
the Wee1 inhibitor MK-1775.
Example 7
Interaction Between Compound (I-C) and MK-1775 in Combination
[0329] A Cdc7 inhibitor was coadministered with MK-1775 to Colo205
cells, and the number of cells that died was examined, in the same
way as in Example 1 except that compound (I-C) was used as the Cdc7
inhibitor, and the concentration of compound (I-C) was set to 0.1
.mu.M or 0.3 .mu.M. The results are shown in FIG. 7. Even when
compound (I-C) was used, the induced cell death was found to be
synergistically increased by the coadministration with the Wee1
inhibitor MK-1775.
Example 8
Interaction Between Compound (I-F) or Compound (I-G) and MK-1775 in
Combination
[0330] A Cdc7 inhibitor was coadministered with MK-1775 to Colo205
cells, and the number of cells that died was examined, in the same
way as in Example 1 except that: compound (I-F) or compound (I-G)
was used as the Cdc7 inhibitor; the concentration thereof was set
to 0.1 .mu.M or 0.3 .mu.M; and the concentration of MK-1775 was set
to 0.5 M. The results are shown in FIG. 8. Even when compound (I-F)
or compound (I-G) was used, the induced cell death was found to be
synergistically increased by the coadministration with the Wee1
inhibitor MK-1775. In this context, the compound (I-G) is compound
F26 described in the specifications of JP 2009-531373 A and
International Publication No. WO 2007/110344, and the compound
(I-F) is a Cdc7/Cdk9 inhibitor of Merck KGaA (catalog No.:
217707-5MGCN), as mentioned above.
Example 9
Interaction Between Compound (I-D) or Compound (I-E) and Different
M-Phase Promoter in Combination
[0331] A Cdc7 inhibitor and an M-phase promoter were coadministered
in combination to Colo205 cells, and the number of cells that died
was examined, in the same way as in Example 1 except that: compound
(I-D) or compound (I-E) was used as the Cdc7 inhibitor; the
concentration thereof was set to 0.3 .mu.M or 0.1 .mu.M; a Chk1
inhibitor SCH900776 was used instead of the Wee1 inhibitor MK-1775
as the M-phase promoter; and the concentration thereof was set to
3.3 .mu.M. The results are shown in FIG. 9. Even when SCH900776
(SCH) was used as a different M-phase promoter, the induced cell
death was found to be synergistically increased by the
coadministration with compound (I-D) or compound (I-E).
Example 10
Interaction Between Compound (I-D) or Compound (I-E) and Different
M-Phase Promoter in Combination
[0332] A Cdc7 inhibitor and an M-phase promoter were coadministered
in combination to Colo205 cells, and the number of cells that died
was examined, in the same way as in Example 1 except that: compound
(I-D) or compound (I-E) was used as the Cdc7 inhibitor; the
concentration thereof was set to 0.1 .mu.M, 0.03 .mu.M, or 0.3
.mu.M; a Chk1 inhibitor UCN-01 was used instead of the Wee1
inhibitor MK-1775 as the M-phase promoter; and the concentration
thereof was set to 333 nM. The results are shown in FIG. 10. Even
when UCN-01 was used as a different M-phase promoter, the induced
cell death was found to be synergistically increased by the
coadministration with compound (I-D) or compound (I-E).
Example 11
Interaction Between Compound (I-D) or Compound (I-E) and Different
M-Phase Promoter in Combination
[0333] A Cdc7 inhibitor and an M-phase promoter were coadministered
in combination to Colo205 cells, and the number of cells that died
was examined, in the same way as in Example 1 except that: compound
(I-D) or compound (I-E) was used as the Cdc7 inhibitor; the
concentration thereof was set to 0.1 .mu.M, 0.03 .mu.M, or 0.3
.mu.M; an Hsp90 inhibitor geldanamycin was used instead of the Wee1
inhibitor MK-1775 as the M-phase promoter; and the concentration
thereof was set to 10 nM or 33 nM. The results are shown in FIG.
11. Even when geldanamycin was used as a different M-phase
promoter, the induced cell death was found to be synergistically
increased by the coadministration with compound (I-D) or compound
(I-E).
Example 12
EVALUATION of Interaction Between Compound (I-D) or Compound (I-E)
and Wee1 Inhibitor as M-Phase Promoter in Combination Using BLISS
Score
[0334] The BLISS scoring was used to analyze the effect of the Cdc7
inhibitor and the Wee1 inhibitor (MK-1775) used in combination on
the inhibition of cancer cell growth.
(Culture of Cells Used)
[0335] Human mammary gland cancer MDA-MB-231 cells (ATCC No.
HTB-26) were cultured in a T75 flask using a Leibovitz's L-15
medium (Life Technologies Corp., #11415-064) supplemented with 10%
fetal bovine serum (FBS) (Equitech-Bio, Inc.) and 5%
penicillin-streptomycin (Nacalai Tesque, Inc.) (hereinafter,
referred to as a growth medium) in a 37.degree. C. incubator
(without CO.sub.2).
(Inoculation of Cell Suspension to Plate)
[0336] The MDA-MB-231 cells were resuspended at a cell density of
0.035.times.10.sup.6 cells/mL in a fresh growth medium. Then, the
cell suspension was added at 100 .mu.L/well to a 96-well cell
culture plate (Falcon, #353075) and cultured overnight in a
37.degree. C. incubator (3,500 cells per well). Approximately 24
hours after the inoculation, the medium was removed, and 80 .mu.L
of a fresh growth medium was added to each well.
(Addition of Compound to be Tested)
[0337] A 10 mM DMSO stock solution of a first test compound Cdc7
inhibitor (compound (I-D) or compound (I-E) was diluted into 10
concentrations (10 mM, 5 mM, 2.5 mM, 1.25 mM, 0.625 mM, 0.313 mM,
0.156 mM, 0.0781 mM, 0.0391 mM, and 0.0195 mM) with DMSO. Each
solution was further diluted 100-fold with a growth medium and
added at 10 .mu.L/well to the plate (1000-fold dilution; final
administration concentration range: 19.5 to 10000 nM). A 10 mM DMSO
stock solution of a second test compound Wee1 inhibitor (MK-1775)
was diluted into 8 concentrations (1 mM, 0.5 mM, 0.25 mM, 0.125 mM,
0.0625 mM, 0.0313 mM, 0.0156 mM, and 0.00781 mM) with DMSO. Each
solution was further diluted 100-fold with a growth medium and
added at 10 .mu.L/well to the plate (1000-fold dilution; final
administration concentration range: 7.81 to 1000 nM). Also, DMSO
was diluted 100-fold with a growth medium and added at 20
.mu.L/well to the plate (control wells).
(Measurement of Cell Growth Inhibitory Effect)
[0338] After the addition of the compounds, the cells were
incubated for 72 hours. Then, Mildform.RTM. 10N (Wako Pure Chemical
Industries, Ltd., #133-10311) was added at 100 .mu.L/well and
incubated at room temperature for 45 minutes to fix the cells. Each
well was washed with 100 .mu.L of phosphate-buffered saline (PBS)
three times. Hoechst 33342 (Life Technologies Corp., #H3570)
diluted into 2 .mu.M with PBS was added at 100 L/well and incubated
at room temperature for 30 minutes to stain the nuclei. Each well
was washed with 100 .mu.L of PBS three times. Then, the number of
nuclei (the number of cells) was measured using a cell image
analyzer (ArrayScan VTI HCS Reader, Thermo Fischer Scientific,
Inc.) (Ex/Em=350/461 nm).
(Calculation of Cell Growth Inhibitory Effect)
[0339] After 72 hours, the average number from the control wells
was used as the number of untreated control cells (G.sub.unt72),
and the average number from the compound-treated wells was used as
the number of compound-treated cells (G.sub.72). Wells in which the
medium was merely replaced 24 hours after the cell inoculation were
counted as an initial value and used as the initial number of cells
(G.sub.0).
[0340] The rate of cell growth in each well was calculated
according to the following expression:
Rate of cell growth G=((G.sub.72-G.sub.0)/(G.sub.unt72-G.sub.0)
The percent rate of inhibition of cell growth in each well was
calculated according to the following expression, and the results
are shown in FIGS. 12 and 13:
Rate of inhibition of cell growth GI (%)=100.times.(1-G)
(Evaluation Based on BLISS Score)
[0341] Assuming that the first test compound and the second test
compound each acted as a single agent (i.e., the rate of cell
growth when the concentration of either of the compounds was 0),
the theoretical BLISS independence (BLISS.sub.in) of each well can
be calculated according to the following expression:
BLISS.sub.in=G(First test compound).times.G(Second test
compound)
[0342] The BLISS score of each well can be determined from the
difference between the theoretical value BLISS.sub.in and the
actually measured value of the rate of cell growth. If the BLISS
score is a positive number, the synergistic effect appears to be
present.
BLISS score=100.times.(BLISS.sub.in-G)
[0343] The results of this test are shown in FIGS. 14 and 15.
[0344] These results indicate that the combined use of the Cdc7
inhibitor compound (I-D) or compound (I-E) and the Wee1 inhibitor
(MK-1775) synergistically inhibits the growth of cancer cells.
INDUSTRIAL APPLICABILITY
[0345] The present invention provides an anticancer composition of
a Cdc7 inhibitor and an M-phase promoter that brings about cell
death more efficiently with higher selectivity and specificity for
a wide range of cancer cells, as compared with use of the Cdc7
inhibitor or the M-phase promoter alone.
* * * * *